Concord Drugs (BOM:538965) Cyclically Adjusted PB Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
65 GF Score
Price ₹79.67
GF Value ₹64.54
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Concord Drugs Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Concord Drugs  (BOM:538965) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Concord Drugs Cyclically Adjusted PB Ratio Related Terms


Concord Drugs Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Cyclically Adjusted PB Ratio Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.04 0.89 1.91

Concord Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.85 0.00 1.91 0.00

BOM:538965 vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Cyclically Adjusted PB Ratio falls into.


BOM:538965
65GF Score
Concord Drugs Ltd BOM:538965
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Concord Drugs's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Concord Drugs's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Concord Drugs Quarterly Data

Book Value per Share CPI Adj_Book
201609 21.642 105.961 34.182
201612 0.000 105.196 0.000
201703 26.219 105.196 41.712
201706 0.000 107.109 0.000
201709 21.208 109.021 32.556
201712 0.000 109.404 0.000
201803 24.578 109.786 37.466
201806 0.000 111.317 0.000
201809 25.995 115.142 37.783
201812 0.000 115.142 0.000
201903 29.454 118.202 41.703
201906 0.000 120.880 0.000
201909 26.701 123.175 36.279
201912 0.000 126.235 0.000
202003 26.858 124.705 36.044
202006 0.000 127.000 0.000
202009 27.139 130.118 34.906
202012 0.000 130.889 0.000
202103 30.611 131.771 38.878
202106 0.000 134.084 0.000
202109 31.921 135.847 39.325
202112 0.000 138.161 0.000
202203 32.434 138.822 39.101
202206 0.000 142.347 0.000
202209 32.856 144.661 38.011
202212 0.000 145.763 0.000
202303 34.036 146.865 38.785
202306 0.000 150.280 0.000
202309 35.578 151.492 39.304
202312 0.000 152.924 0.000
202403 33.818 153.035 36.983
202406 0.000 155.789 0.000
202409 33.884 157.882 35.918
202412 0.000 158.323 0.000
202503 34.114 157.552 36.237
202506 0.000 159.755 0.000
202509 34.419 162.289 35.494
202512 0.000 163.281 0.000
202603 36.823 164.272 37.515
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹79.67 is trading 23.4% above its estimated GF Value™ of ₹64.54. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹64.54 vs. price of ₹79.67 (23.4% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
65GF Score

Get the complete analysis for BOM:538965

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹79.67
Price
₹64.54
GF Value